Full history for every metric is available with a Kvantra account
Oncimmune Holdings plc (ONC.L)
Key financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 1 | 4 | 4 | 1 | 3 | 3 |
| Operating profit | £m | -3 | -3 | |||||
| Net profit | £m | -8 | -8 | -5 | -10 | 4 | -4 | -4 |
| EPS reported | £ | -0.05 | -0.05 | |||||
| Operating cashflow per share | £ | -0.05 | -0.05 | |||||
| Capex per share | £ | 0.00 | 0.00 | |||||
| FCF per share | £ | -0.05 | -0.05 | |||||
| Free cash flow | £m | -3 | -3 | |||||
| Net debt | £m | 4 | 4 | |||||
| Book value equity | £m | -2 | -2 | |||||
| Book value per share | £ | -0.03 | -0.03 | |||||
| Number of shares | m | 74.14 | 74.14 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -5.42 | -0.53 | |||||
| P/S LTM | x | 4.75 | 0.47 | |||||
| P/FCF LTM | x | -3.84 | -0.38 | |||||
| EV/EBITDA LTM | x | -5.76 | -1.87 | |||||
| EV/Sales LTM | x | 6.31 | 2.01 | |||||
| Earnings Yield LTM | % | -27.88% | -429.24% | |||||
| FCF Yield | % | -26.05% | -266.05% | |||||
| Quality | ||||||||
| ROE | % | 151.23% | 416.53% | |||||
| ROIC | % | -69.94% | -69.94% | |||||
| Operating margin | % | -117.78% | -117.78% | |||||
| Gross margin | % | 44.94% | 44.94% | |||||
| FCF/Sales | % | -123.77% | -123.77% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +137.76% | +137.76% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.66 | -0.66 | |||||
| Net Debt/EBITDA | x | -1.42 | -1.42 | |||||
| EBIT/Net interest | x | -4.54 | -4.54 | |||||
| Net debt/market cap | % | 32.44% | 331.26% | |||||
| Net debt/Equity | x | -1.76 | -1.76 | |||||
| Gross debt/equity | x | -2.14 | -2.14 | |||||
Company overview
Oncimmune Holdings plc specializes in creating and bringing to market advanced diagnostic technologies for cancer, serving regions across the United Kingdom, North America, Europe, and globally. A cornerstone product is EarlyCDT-Lung, an immunodiagnostic test specifically designed for the detection and identification of lung cancer. The company further advances its capabilities with SeroTag, a robust platform dedicated to discovering and validating biomarkers vital for patient stratification across numerous cancer types, infectious ailments, and a range of autoimmune disorders. Additionally, they provide NavigAID, a bespoke panel for disease characterization. Founded in 2015, Oncimmune Holdings plc operates from its base in Nottingham, UK.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Oncimmune Holdings plc (ONC.L)
Oncimmune Holdings plc specializes in creating and bringing to market advanced diagnostic technologies for cancer, serving regions across the United Kingdom, North America, Europe, and globally. A cornerstone product is EarlyCDT-Lung, an immunodiagnostic test specifically designed for the detection and identification of lung cancer. The company further advances its capabilities with SeroTag, a robust platform dedicated to discovering and validating biomarkers vital for patient stratification across numerous cancer types, infectious ailments, and a range of autoimmune disorders. Additionally, they provide NavigAID, a bespoke panel for disease characterization. Founded in 2015, Oncimmune Holdings plc operates from its base in Nottingham, UK.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free